- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Trabeculoplasty may benefit patients of glaucoma and ocular surface disease: study
![Trabeculoplasty may benefit patients of glaucoma and ocular surface disease: study Trabeculoplasty may benefit patients of glaucoma and ocular surface disease: study](https://medicaldialogues.in/h-upload/2020/01/23/750x450_123418-glaucoma-test.jpg)
Finland: Trabeculectomy and the resulting cessation of topical glaucoma medication are very beneficial to the ocular surface as indicated by clinical signs and tear proteomics, finds a recent study in the journal Acta Ophthalmologica. Further, throughout the 1‐year follow‐up, the state of conjunctiva improved while there was an increase in the lipid transport‐associated functions and a decrease in the levels of pro‐inflammatory proteins.
Anu Vaajanen, Tays Eye Centre, Tampere University Hospital, Tampere, Finland, and colleagues reported changes in the ocular surface and tear proteomics after discontinuation of chronic glaucoma medication.
The researchers recruited patients who required trabeculectomy from the glaucoma clinic of Tampere University Hospital, Finland. The report included fifty‐seven patients with the previous history of anti‐glaucomatous eye drops (8.1 ± 6.8 years) and underwent a successful trabeculectomy.
Outcomes of interest were conjunctival redness grading, tear secretion (Schirmer I), and tear film proteomics (SWATH‐MS) in addition to a thorough clinical examination. The protocol included five-time points: preoperative visit and postoperative visits at months 1, 3, 6, and 12. All parameters measured were compared to the corresponding preoperative levels of each individual.
Also Read: Patients with highest IOP benefit most from laser therapy in glaucoma: Study
Key findings of the study include:
- Conjunctival redness and irritation were significantly reduced during follow‐up, while tear production remained unchanged.
- Protein profiles of the tear film indicated significant changes in the ocular surface.
- Lipid transport was increased while several pro‐inflammatory proteins were consistently decreased after the surgery.
Ocular surface recovery from the discontinuation of topical glaucoma medications is a long process. Therefore it is advisable for clinicians to consider either selective laser trabeculoplasty or non-preservative topical glaucoma medications as initial treatment in patients with open-angle glaucoma and concomitant ocular surface disease.
Also Read: Glaucoma study findings emphasise need for regular eye checks
The study, "The effect of successful trabeculectomy on the ocular surface and tear proteomics—a prospective cohort study with 1‐year follow‐up," is published in the journal Acta Ophthalmologica.
DOI: https://doi.org/10.1111/aos.14526
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751